FGFR4 and hepatocellular carcinoma: Other FGFR4 inhibitors such as BLU‐554 and H3B‐6527 have been investigated in Phase 1 and Phase 1/2 clinical trials for HCC and displayed potent anticancer abilities.13, 24, 25, 26, 27